Context sidebar
03.07.2020
In an international comparison of the processing time for scientific assessments, Swissmedic is on a par with the fastest authorities
01.07.2020
Swissmedic is changing its practice
Avoiding text review rounds
Type II variations now possible
01.06.2020
ZL000_00_027e_WL
28.05.2020
Extension of the transition period
26.05.2020
Tucatinib for the treatment of a particularly aggressive type of breast cancer reviewed in four months
13.05.2020
This approval in Switzerland paves the way for the approval and introduction in low- and middle-income countries
06.05.2020
ZL000_00_019e_WL
04.05.2020
ZL000_00_022e_WL
21.04.2020
The new requirements enter into force immediately
03.04.2020
COVID-19: Deadline extension
01.04.2020
ZL109_00_001e_WL
26.03.2020
Independent experts as an additional quality-assurance element in the authorisation process
25.02.2020
Swissmedic authorises a new active substance (NAS) under the ACSS Consortium initiative for the first time
Allocation of CHM to Case Management (XLS, 4 MB, 01.06.2020)
Top of page
